Diagnosis and Management of Rheumatoid Arthritis: A Review

  title={Diagnosis and Management of Rheumatoid Arthritis: A Review},
  author={Daniel Aletaha and Josef S. Smolen},
Importance Rheumatoid arthritis (RA) occurs in about 5 per 1000 people and can lead to severe joint damage and disability. Significant progress has been made over the past 2 decades regarding understanding of disease pathophysiology, optimal outcome measures, and effective treatment strategies, including the recognition of the importance of diagnosing and treating RA early. Observations Early diagnosis and treatment of RA can avert or substantially slow progression of joint damage in up to 90… 

Figures and Tables from this paper

Management of Rheumatoid Arthritis: An Overview
A comprehensive perspective on the management of RA is offered, by centralizing the existing data provided by significant literature, emphasizing the importance of an early and accurate diagnosis associated with optimal personalized treatment in order to achieve better outcomes for RA patients.
Treatment Guidelines in Rheumatoid Arthritis—Optimizing the Best of Both Worlds
This review discusses management guidelines for RA and their practical application by discussing clinical scenarios commonly encountered in rheumatology practice and discusses three RA cases to illustrate key aspects of treatment guidelines.
An update on novel therapeutic intervention in Rheumatoid arthritis.
Biologic discontinuation strategies and outcomes in patients with rheumatoid arthritis
This narrative review illustrates the rationales for dose tapering and expands to provide an overview of the efficacy of the different available strategies for reducing the exposure to biologic drugs in patients achieving a sustained clinical response.
Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis
This review summarizes the current understanding of the underlying pathomechanism, diagnosis of RA, as well as the mode of action, clinical benefits, and side-effects of the currently available DMARDs.
[Rheumatoid arthritis: achievements and unresolved issues].
Research is needed which should be directed to investigation of a heterogeneity of RA pathogenetic mechanisms and to elaboration of approaches to its early diagnosis as well as to improving methods for monitoring a disease activity, biomarkers of efficacy and resistance to therapy, and finally, to developing of a differentiated therapy.
Routine treatment of rheumatoid arthritis with biologics and targeted agents: changes in patients and their response over 15 years
The fact that the DAS28 at 6 months remained constant is both good and bad news: many patients can expect to reach low disease activity levels after starting treatment with bDMARDs or ts DMARDs, but early treatment (and a more favourable starting position) apparently does not lead to more remissions.
Increased disease activity in early arthritis patients with anti-carbamylated protein antibodies
The results show the association of ACarPA with increased levels of all the disease activity measures in the first visit after arthritis onset, but the associations were more significant with the high levels in local measures of inflammation and physician assessment than with the increases in systemic inflammation and patient-reported outcomes.


Rheumatoid arthritis
Editorial: Prevention of Rheumatoid Arthritis: Now Is the Time, but How to Proceed?
A further analysis of the data from the PROMPT study is reported, this time to address the issue that perhaps earlier analyses yielded false-negative results because patients at low risk of developing classifiable RA were included and if the individuals at highest risk of future RA could be identified, a benefit of treatment might be apparent.
What is the natural history of rheumatoid arthritis?
Individual patients with RA who are at risk for early mortality may be identified through clinical markers, including many involved joints, comorbid cardiovascular disease, and poor functional status according to questionnaires and physical measures.
Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide
Clinical evidence strongly supports the observations that structural damage occurs early in active RA and that early DMARD treatment improves the long term outcome of the disease.
Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges
The data available suggest that, in most patients with established disease, cessation of biologic therapy will be followed by disease flares, whereas a reduction of dose or an increase in the interval between doses enables maintenance of treatment success, which underscores the importance of research into the cause of RA so that curative therapies can be developed.
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.
In patients with early RA, initial combination therapy including either prednisone or infliximab resulted in earlier functional improvement and less radiographic damage after 1 year than did sequential monotherapy or step-up combination therapy.
Future therapeutic targets in rheumatoid arthritis?
There is a great interest in the granulocyte macrophage-colony stimulating factor pathway, Bruton’s tyrosine kinase pathway, phosphoinositide-3-kinases pathway, neural stimulation and dendritic cell-based therapeutics, and the therapeutic potential of these novel approaches are discussed.
Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial
In early RA, a MSUS-driven T2T strategy led to more intensive treatment, but was not associated with significantly better clinical or imaging outcomes than a DAS28-driven strategy.
Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial.
High CRP level, high ESR, or persistent disease activity was associated with greater radiographic progression in the group taking MTX alone, while little radiography progression was seen in patients receiving both MTX and infliximab, regardless of the abnormal levels of these traditional predictors.